Experienced Industry Executive Dr. Steve Cutler to Join ICON
Leadership Team
DUBLIN--(BUSINESS WIRE)--
ICON plc.(NASDAQ:ICLR)(ISIN:IE0005711209), a global provider of
outsourced development services to the pharmaceutical, biotechnology and
medical device industries, today announced that Dr. Steve Cutler will
join the company as Group President, Clinical Research Services.
Dr. Cutler has over 23 years' experience within the pharmaceutical and
CRO industry and joins ICON from Kendle where he held the position of
Chief Executive Officer, having previously served as Kendle's Chief
Operating Officer. Prior to Kendle, Dr. Cutler spent 14 years with
Quintiles where he served as Senior Vice President, Global Project
Management; Senior Vice President, Clinical, Medical and Regulatory;
Senior Vice President, Project Management - Europe; and Vice President,
Oncology - Europe as well as regional leadership positions in South
Africa and Australia. Prior to joining Quintiles Dr. Cutler held
positions with Sandoz (now Novartis) in Australia and Europe. He holds a
B.Sc. and a PhD from the University of Sydney and a Masters of Business
Administration from the University of Birmingham (UK).
ICON also announced that Mr Alan Morgan, the former Group President,
Clinical Research Services, has resigned from his position and will
leave the organisation at the end of April 2012 to pursue other
opportunities.
Commenting on the organisational changes, Ciaran Murray CEO of ICON said
"We are delighted to welcome Steve to ICON. He is joining us at a time
when we are building the foundations for long-term sustainable growth
and his experience and proven leadership capabilities will be important
as we continue to enhance our position as the global CRO partner of
choice for the Biopharma industry. I would also like to thank Alan for
his commitment to ICON and acknowledge the contribution he has made to
our organisation. I wish him every success in the future."
About ICON plc
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The Company
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. ICON currently has around 8300 employees,
operating from 79 locations in 38 countries.
Further information is available at www.iconplc.com
DISCLOSURE NOTICE: The statements made in this press
release may contain forward-looking statements that involve a number of
risks and uncertainties. In addition to the matters described in this
press release, the ability to maintain large client contracts or enter
into new contracts, maintain client relationships and the ability to
manage the opening of new offices, the integration of new business
mergers and acquisitions, as well as other risks and uncertainties
detailed from time to time in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by
ICON. ICON disclaims any intent or obligation to update these
forward-looking statements.
ICON/ICLR-F
ICON
Investor Relations 1-888-381-7923
or
Brendan Brennan
Chief Financial Officer +353-1-291-2000
or
Sam Farthing VP
Investor Relations +353-1-291-2000
Source: ICON plc
News Provided by Acquire Media
